European Guideline (<scp>EuroGuiDerm</scp>) on atopic eczema: Living update

The evidence- and consensus-based living guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. The original EuroGuiDerm Guideline on atopic eczema was published in June 2022. Since then, the part of the guideline dealing with systemic therapy has been updated twice. This paper summarizes the results of the second update. Twenty-eight experts (including clinicians and patient representatives) from 12 European countries participated. The updated guideline provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab and tralokinumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib and upadacitinib). Additionally, the updated guidelines address considerations for paediatric, adolescent, pregnant and breastfeeding patients. For all other aspects, please refer to the 2022 version.

Authors

Institutions

Publication Details

Journal
Journal of the European Academy of Dermatology and Venereology
Published
2025-05-02
DOI
https://doi.org/10.1111/jdv.20639
Citations
31
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
62.15
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Zsuzsanna Szalai, Eva Maria Rehbinder, N. Aszodi, Johannes Ring et al.
31 citations
Journal of the European Academy of Dermatology and Venereology
Dermatology and Skin Diseases
62.15
article

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Zsuzsanna Szalai, Eva Maria Rehbinder, N. Aszodi, Johannes Ring, Thomas Werfel, Giampiero Girolomoni, Krisztián Gáspár, Mariateresa Rossi, B.W.M. Arents, Nicole Fosse, Stamatios Gregoriou, Mette Deleuran, Uwe Gieler, T. Bieber, Carsten Flohr, Alexander Nast, Antonio Torrelo, S. Barbarot, Louise A. A. Gerbens, E. Serra‐Baldrich, Maria Kinberger, Piergiacomo Calzavara‐Pinton, Charlotte Gotthard Mortz, Uffe Nygaard, Andreas Wollenberg, Stéphanie Christen‐Zaech, Jacek Cezary Szepietowski, Ricardo Niklas Werner, Dagmar Simon, Martin Dittmann, Helen A. Brough, Simon Holland
article en
31 citations

Abstract

The evidence- and consensus-based living guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. The original EuroGuiDerm Guideline on atopic eczema was published in June 2022. Since then, the part of the guideline dealing with systemic therapy has been updated twice. This paper summarizes the results of the second update. Twenty-eight experts (including clinicians and patient representatives) from 12 European countries participated. The updated guideline provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab and tralokinumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib and upadacitinib). Additionally, the updated guidelines address considerations for paediatric, adolescent, pregnant and breastfeeding patients. For all other aspects, please refer to the 2022 version.

Journal of the European Academy of Dermatology and VenereologyVol. 39(9)
University of Bern (CH), Wrocław University of Science and Technology (PL), University of Verona (IT), Oslo University Hospital (NO), St Thomas' Hospital (GB), University of Debrecen (HU), University of Southern Denmark (DK), King's College London (GB), University of Oslo (NO), Guy's and St Thomas' NHS Foundation Trust (GB), Justus-Liebig-Universität Gießen (DE), National and Kapodistrian University of Athens (GR), University Hospital Bonn (DE), University Hospital of Bern (CH), Odense University Hospital (DK), Hospital de Sant Pau (ES), University Hospital Augsburg (DE), Centre Hospitalier Universitaire Vaudois (CH), Aarhus University Hospital (DK), University Hospital of Basel (CH), Amsterdam UMC Location University of Amsterdam (NL), Medizinische Hochschule Hannover (DE), Humboldt-Universität zu Berlin (DE), Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Amsterdam Neuroscience (NL), Hospital Infantil Universitario Niño Jesús (ES), CK-CARE (CH), European Federation of Allergy and Airways Diseases Patients Associations (BE), Evelina London Children's Healthcare (GB), Amsterdam University Medical Centers (NL), PhysioPathologie des Adaptations Nutritionnelles (FR), AGH University of Krakow (PL), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE), University of Brescia (IT), Ludwig-Maximilians-Universität München (DE), University of Amsterdam (NL), University of Lübeck (DE), Nantes Université (FR), University of Lausanne (CH)
Partnerships for the goals
Openalex Percentile: Top 0%
Dermatology and Skin Diseases
62.15
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.